Skip to main content
. 2012 Jun;3(2):130–138. doi: 10.3978/j.issn.2078-6891.2011.025

Table 3. Adjuvant therapy with hepatic arterial infusion plus newer chemotherapy agent after resection of colorectal liver metastases.

Ref. No Author (year) No. of Patients Treatment DFS OS
(53) Kemeny (2003) 96 HAI FUDR/Dex
SYS IRI
47% 2 years 89% 2 years
(54) Kemeny (2009) 35 HAI FUDR/Dex
SYS OXA+5-FU/LV
88% 3 years 88% 3 years
* House (2009)a 250 HAI FUDR/Dex+
SYS OXA+5-FU/LV or
IRI+5-FU/LV vs.
SYS alone no HAI
48% 5 years
25% 5 years
77% 5 years
55% 5 years
(55) Alberts (2010) 76 HAI FUDR/Dex
SYS OXA+CAP
32.7 mo 88% 2 years
(56) Kemeny (2011) 73 HAI FUDR/Dex
SYS no Bevacizumab
SYS + Bevacizumab
46% 4 years
37% 4 years
85% 4 years
81% 4 years

Abbreviations: HAI, hepatic arterial infusion; FUDR, floxuridine; Dex, dexamethasone; SYS, systemic; IRI, irinotecan; mo, months; OS, overall survival; DFS, disease-free survival; OXA, oxaliplatin; 5-FU, 5-Fluorouracil; LV, leucovorin; CAP, capecitabine. *Accepted for publication in Annals of Surgery, 2011. aRetrospective; Median.